US Stock MarketDetailed Quotes

MRK Merck & Co

Watchlist
  • 131.200
  • +0.480+0.37%
Close Apr 26 16:00 ET
  • 131.968
  • +0.768+0.59%
Post 19:34 ET
332.33BMarket Cap145.78P/E (TTM)

Merck & Co Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
(Q2)Jun 30, 2022
(Q1)Mar 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-31.89%13.01B
-94.45%246M
37.75%7.72B
-13.90%3.7B
-71.88%1.34B
45.52%19.1B
-13.05%4.43B
16.78%5.6B
116.18%4.3B
283.95%4.76B
Net income from continuing operations
-97.40%377M
-140.62%-1.23B
46.06%4.75B
-251.23%-5.97B
-34.41%2.83B
17.54%14.53B
-21.08%3.02B
-28.86%3.25B
225.29%3.95B
56.68%4.31B
Operating gains losses
-123.96%-340M
-272.41%-100M
-90.81%34M
-37.81%176M
-163.56%-450M
173.14%1.42B
114.32%58M
154.33%370M
201.07%283M
223.34%708M
Depreciation and amortization
-0.95%3.87B
8.07%964M
5.74%1.01B
-3.73%903M
-11.52%991M
21.62%3.91B
6.83%892M
26.35%959M
28.85%938M
25.56%1.12B
Deferred tax
-21.11%-1.9B
-203.26%-931M
49.17%-336M
-35.50%-355M
18.05%-277M
-938.50%-1.57B
-293.08%-307M
-66,000.00%-661M
-2,481.82%-262M
-1,977.78%-338M
Other non cash items
804.23%11.76B
240.15%449M
-126.76%-99M
1,488.26%10.42B
595.80%995M
-44.90%1.3B
-56.86%132M
116.37%370M
-60.19%656M
-39.41%143M
Change In working capital
20.74%-2.21B
141.50%144M
727.76%2.18B
-16.94%-1.64B
-122.48%-2.89B
27.53%-2.78B
-671.11%-347M
289.21%263M
4.37%-1.4B
40.74%-1.3B
-Change in receivables
-78.26%-1.15B
----
----
----
----
68.32%-644M
----
----
----
----
-Change in inventory
-406.83%-816M
----
----
----
----
76.11%-161M
----
----
----
----
-Change in payables and accrued expense
3,843.90%1.62B
----
----
----
----
-71.13%41M
----
----
----
----
-Change in other current liabilities
183.67%456M
----
----
----
----
-212.60%-545M
----
----
----
----
-Change in other working capital
-57.09%-2.31B
----
----
----
----
16.21%-1.47B
----
----
----
----
Cash from discontinued investing activities
0
0
Operating cash flow
-31.89%13.01B
-94.45%246M
37.75%7.72B
-13.90%3.7B
-71.88%1.34B
35.34%19.1B
-11.95%4.43B
16.78%5.6B
72.77%4.3B
165.83%4.76B
Investing cash flow
Cash flow from continuing investing activities
-183.93%-14.08B
103.03%53M
65.28%-334M
-962.49%-11.44B
-101.11%-2.36B
69.79%-4.96B
85.49%-1.75B
9.33%-962M
58.97%-1.08B
-70.99%-1.17B
Capital expenditure reported
11.96%-3.86B
13.93%-989M
19.89%-902M
14.53%-965M
-2.34%-1.01B
1.35%-4.39B
4.88%-1.15B
3.92%-1.13B
-14.50%-1.13B
9.06%-984M
Net business purchase and sale
-9,843.80%-12.03B
--0
--0
---10.71B
---1.33B
99.06%-121M
--0
-12,200.00%-121M
--0
--0
Net investment purchase and sale
482.61%1.85B
320.54%1.06B
77.88%587M
550.00%260M
83.29%-62M
-147.12%-483M
-191.12%-482M
197.30%330M
--40M
-196.36%-371M
Net other investing changes
-212.50%-36M
82.05%-21M
57.78%-19M
-375.00%-33M
-79.67%37M
135.16%32M
-10.38%-117M
-4,400.00%-45M
140.00%12M
1,554.55%182M
Cash from discontinued investing activities
Investing cash flow
-183.93%-14.08B
103.03%53M
65.28%-334M
-962.49%-11.44B
-101.11%-2.36B
70.04%-4.96B
85.49%-1.75B
9.33%-962M
60.21%-1.08B
-58.94%-1.17B
Financing cash flow
Cash flow from continuing financing activities
47.25%-4.81B
-44.47%-2.25B
-57.99%-4.27B
311.48%3.76B
33.44%-2.05B
-394.45%-9.12B
-129.84%-1.55B
-18.82%-2.7B
-178.56%-1.78B
-47.09%-3.09B
Net issuance payments of debt
285.87%4.18B
-200.00%-3M
-94.50%-1.95B
--6.13B
99.92%-1M
-238.01%-2.25B
-100.01%-1M
---1B
--0
-242.47%-1.25B
Net common stock issuance
---1.35B
---393M
---466M
---338M
---149M
--0
--0
--0
--0
--0
Cash dividends paid
-6.18%-7.45B
-5.83%-1.85B
-6.18%-1.86B
-6.50%-1.89B
-6.19%-1.85B
-6.08%-7.01B
-6.51%-1.75B
-5.94%-1.75B
-5.80%-1.77B
-6.08%-1.75B
Proceeds from stock option exercised by employees
-67.45%125M
-97.74%6M
-30.00%7M
-15.46%82M
150.00%30M
90.10%384M
97.76%265M
-41.18%10M
130.95%97M
33.33%12M
Net other financing activities
-36.67%-328M
95.59%-3M
-128.57%-10M
-125.00%-234M
21.36%-81M
-102.75%-240M
-106.06%-68M
159.32%35M
-101.17%-104M
-6.19%-103M
Cash from discontinued financing activities
0
0
Financing cash flow
47.25%-4.81B
-44.47%-2.25B
-57.99%-4.27B
311.48%3.76B
33.44%-2.05B
-451.68%-9.12B
-129.84%-1.55B
-18.82%-2.7B
-201.08%-1.78B
-47.09%-3.09B
Net cash flow
Beginning cash position
56.40%12.77B
-23.14%8.67B
-41.43%5.71B
13.61%9.79B
56.40%12.77B
0.17%8.17B
12.27%11.28B
13.01%9.75B
25.17%8.61B
0.02%8.17B
Current changes in cash
-217.36%-5.89B
-272.52%-1.95B
60.68%3.11B
-374.93%-3.98B
-712.35%-3.07B
3,312.24%5.02B
162.29%1.13B
32.56%1.94B
-6.04%1.45B
148.04%502M
Effect of exchange rate changes
105.61%23M
-49.18%186M
61.89%-157M
69.90%-93M
258.18%87M
-208.27%-410M
638.24%366M
-795.65%-412M
-496.15%-309M
43.30%-55M
End cash Position
-45.91%6.91B
-45.91%6.91B
-23.14%8.67B
-41.43%5.71B
13.61%9.79B
56.40%12.77B
56.40%12.77B
12.27%11.28B
13.01%9.75B
25.17%8.61B
Free cash flow
-37.83%9.14B
-122.65%-743M
52.26%6.82B
-13.68%2.74B
-91.21%332M
52.23%14.71B
-14.18%3.28B
23.48%4.48B
110.97%3.17B
432.72%3.78B
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022(Q2)Jun 30, 2022(Q1)Mar 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -31.89%13.01B-94.45%246M37.75%7.72B-13.90%3.7B-71.88%1.34B45.52%19.1B-13.05%4.43B16.78%5.6B116.18%4.3B283.95%4.76B
Net income from continuing operations -97.40%377M-140.62%-1.23B46.06%4.75B-251.23%-5.97B-34.41%2.83B17.54%14.53B-21.08%3.02B-28.86%3.25B225.29%3.95B56.68%4.31B
Operating gains losses -123.96%-340M-272.41%-100M-90.81%34M-37.81%176M-163.56%-450M173.14%1.42B114.32%58M154.33%370M201.07%283M223.34%708M
Depreciation and amortization -0.95%3.87B8.07%964M5.74%1.01B-3.73%903M-11.52%991M21.62%3.91B6.83%892M26.35%959M28.85%938M25.56%1.12B
Deferred tax -21.11%-1.9B-203.26%-931M49.17%-336M-35.50%-355M18.05%-277M-938.50%-1.57B-293.08%-307M-66,000.00%-661M-2,481.82%-262M-1,977.78%-338M
Other non cash items 804.23%11.76B240.15%449M-126.76%-99M1,488.26%10.42B595.80%995M-44.90%1.3B-56.86%132M116.37%370M-60.19%656M-39.41%143M
Change In working capital 20.74%-2.21B141.50%144M727.76%2.18B-16.94%-1.64B-122.48%-2.89B27.53%-2.78B-671.11%-347M289.21%263M4.37%-1.4B40.74%-1.3B
-Change in receivables -78.26%-1.15B----------------68.32%-644M----------------
-Change in inventory -406.83%-816M----------------76.11%-161M----------------
-Change in payables and accrued expense 3,843.90%1.62B-----------------71.13%41M----------------
-Change in other current liabilities 183.67%456M-----------------212.60%-545M----------------
-Change in other working capital -57.09%-2.31B----------------16.21%-1.47B----------------
Cash from discontinued investing activities 00
Operating cash flow -31.89%13.01B-94.45%246M37.75%7.72B-13.90%3.7B-71.88%1.34B35.34%19.1B-11.95%4.43B16.78%5.6B72.77%4.3B165.83%4.76B
Investing cash flow
Cash flow from continuing investing activities -183.93%-14.08B103.03%53M65.28%-334M-962.49%-11.44B-101.11%-2.36B69.79%-4.96B85.49%-1.75B9.33%-962M58.97%-1.08B-70.99%-1.17B
Capital expenditure reported 11.96%-3.86B13.93%-989M19.89%-902M14.53%-965M-2.34%-1.01B1.35%-4.39B4.88%-1.15B3.92%-1.13B-14.50%-1.13B9.06%-984M
Net business purchase and sale -9,843.80%-12.03B--0--0---10.71B---1.33B99.06%-121M--0-12,200.00%-121M--0--0
Net investment purchase and sale 482.61%1.85B320.54%1.06B77.88%587M550.00%260M83.29%-62M-147.12%-483M-191.12%-482M197.30%330M--40M-196.36%-371M
Net other investing changes -212.50%-36M82.05%-21M57.78%-19M-375.00%-33M-79.67%37M135.16%32M-10.38%-117M-4,400.00%-45M140.00%12M1,554.55%182M
Cash from discontinued investing activities
Investing cash flow -183.93%-14.08B103.03%53M65.28%-334M-962.49%-11.44B-101.11%-2.36B70.04%-4.96B85.49%-1.75B9.33%-962M60.21%-1.08B-58.94%-1.17B
Financing cash flow
Cash flow from continuing financing activities 47.25%-4.81B-44.47%-2.25B-57.99%-4.27B311.48%3.76B33.44%-2.05B-394.45%-9.12B-129.84%-1.55B-18.82%-2.7B-178.56%-1.78B-47.09%-3.09B
Net issuance payments of debt 285.87%4.18B-200.00%-3M-94.50%-1.95B--6.13B99.92%-1M-238.01%-2.25B-100.01%-1M---1B--0-242.47%-1.25B
Net common stock issuance ---1.35B---393M---466M---338M---149M--0--0--0--0--0
Cash dividends paid -6.18%-7.45B-5.83%-1.85B-6.18%-1.86B-6.50%-1.89B-6.19%-1.85B-6.08%-7.01B-6.51%-1.75B-5.94%-1.75B-5.80%-1.77B-6.08%-1.75B
Proceeds from stock option exercised by employees -67.45%125M-97.74%6M-30.00%7M-15.46%82M150.00%30M90.10%384M97.76%265M-41.18%10M130.95%97M33.33%12M
Net other financing activities -36.67%-328M95.59%-3M-128.57%-10M-125.00%-234M21.36%-81M-102.75%-240M-106.06%-68M159.32%35M-101.17%-104M-6.19%-103M
Cash from discontinued financing activities 00
Financing cash flow 47.25%-4.81B-44.47%-2.25B-57.99%-4.27B311.48%3.76B33.44%-2.05B-451.68%-9.12B-129.84%-1.55B-18.82%-2.7B-201.08%-1.78B-47.09%-3.09B
Net cash flow
Beginning cash position 56.40%12.77B-23.14%8.67B-41.43%5.71B13.61%9.79B56.40%12.77B0.17%8.17B12.27%11.28B13.01%9.75B25.17%8.61B0.02%8.17B
Current changes in cash -217.36%-5.89B-272.52%-1.95B60.68%3.11B-374.93%-3.98B-712.35%-3.07B3,312.24%5.02B162.29%1.13B32.56%1.94B-6.04%1.45B148.04%502M
Effect of exchange rate changes 105.61%23M-49.18%186M61.89%-157M69.90%-93M258.18%87M-208.27%-410M638.24%366M-795.65%-412M-496.15%-309M43.30%-55M
End cash Position -45.91%6.91B-45.91%6.91B-23.14%8.67B-41.43%5.71B13.61%9.79B56.40%12.77B56.40%12.77B12.27%11.28B13.01%9.75B25.17%8.61B
Free cash flow -37.83%9.14B-122.65%-743M52.26%6.82B-13.68%2.74B-91.21%332M52.23%14.71B-14.18%3.28B23.48%4.48B110.97%3.17B432.72%3.78B
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg
Concept Cancer Research
Cancer Research
Intraday+0.03%
ESG Investing
ESG Investing
Intraday-0.12%